Texas Biomedical Research Institute

Background

Founded in 1941 by Tom Slick, the Texas Biomedical Research Institute (Texas Biomed) is an independent, non-profit biomedical research organization based in San Antonio, Texas. The institute is dedicated to advancing global health through innovative research on infectious diseases. Its mission is to pioneer and share scientific breakthroughs that protect individuals and communities worldwide from the threat of infectious diseases. Over the decades, Texas Biomed has gained international recognition for its contributions to understanding and combating diseases such as cardiovascular conditions, diabetes, obesity, cancer, psychiatric disorders, AIDS, hepatitis, malaria, and various viral infections.

Key Strategic Focus

Texas Biomed's strategic focus encompasses several core objectives:

Infectious Disease Research: Conducting basic and translational research to understand the mechanisms of infectious diseases and develop effective interventions.

Vaccine and Therapeutic Development: Accelerating the creation and testing of vaccines and treatments for diseases like Ebola, HIV, Lassa fever, and more.

Genetic and Genomic Studies: Utilizing advanced genomic technologies to identify genetic factors influencing disease susceptibility and resistance.

Collaborative Partnerships: Engaging in strategic alliances with global organizations to enhance research capabilities and expedite the development of medical countermeasures.

The institute employs cutting-edge technologies, including high-containment laboratories and advanced genomic computing facilities, to address global health challenges. Its primary markets include public health sectors, governmental agencies, and international health organizations.

Financials and Funding

As a non-profit entity, Texas Biomed's financial structure relies on a combination of contributions, program services, and investment income. In the fiscal year ending December 2023, the institute reported:

Revenue: $83,244,840

Expenses: $83,762,418

Net Assets: $151,029,442

Notably, 92.1% of the revenue was derived from contributions, highlighting strong support from donors and grantors. The institute has also secured significant funding from federal agencies, including a designation as a prime contractor with the Biomedical Advanced Research and Development Authority (BARDA), opening access to a portfolio of up to $100 million over five years.

Pipeline Development

Texas Biomed's research pipeline includes several key projects:

Vaccine Development: Collaborating with the Coalition for Epidemic Preparedness Innovations (CEPI) to develop vaccines for priority pathogens such as Lassa fever and Nipah virus.

Therapeutic Research: Advancing treatments for diseases like Ebola and HIV through preclinical and clinical studies.

Genetic Studies: Identifying genetic factors influencing susceptibility to diseases like cardiovascular conditions and diabetes.

These projects are at various stages, from preclinical research to clinical trials, with anticipated milestones aligned with global health priorities.

Technological Platform and Innovation

Texas Biomed distinguishes itself through several proprietary technologies and methodologies:

Biosafety Level 4 (BSL-4) Laboratory: The only privately-owned BSL-4 lab in the U.S., enabling safe research on lethal pathogens without existing treatments or vaccines.

AT&T Genomics Computing Center: Houses the world's largest computer cluster dedicated to statistical genetic analysis, facilitating rapid identification of disease-influencing genes.

Southwest National Primate Research Center: Maintains a colony of approximately 2,500 nonhuman primates, providing invaluable models for studying human diseases.

These platforms support advanced research methodologies, including high-throughput genomic sequencing and complex disease modeling.

Leadership Team

Texas Biomed's leadership comprises experienced professionals dedicated to advancing the institute's mission:

Dr. Larry Schlesinger: President and CEO, overseeing strategic direction and research initiatives.

Dr. Joanne Turner: Executive Vice President, Research, leading scientific programs and collaborations.

Bruce Edwards: Executive Vice President, Finance & Administration, and Chief Financial Officer, managing financial operations and administrative functions.

Matt Majors: Vice President, Operations, responsible for operational management and infrastructure development.

These leaders bring extensive experience in biomedical research, administration, and strategic planning, contributing significantly to the institute's growth and impact.

Leadership Changes

In recent years, Texas Biomed has seen strategic appointments to strengthen its leadership team. Notably, Dr. Joanne Turner joined as Executive Vice President, Research, bringing expertise in immunology and infectious diseases. These appointments align with the institute's commitment to enhancing its research capabilities and global collaborations.

Competitor Profile

Market Insights and Dynamics

The biomedical research sector is characterized by rapid technological advancements and a growing emphasis on infectious disease research, especially in the wake of global health crises. The market is competitive, with institutions striving to secure funding, attract top talent, and establish partnerships to advance their research agendas.